Cargando…
A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy
Herein, A non-invasive pathomics approach was developed to reveal the methylation status in patients with cervical squamous cell carcinoma and predict clinical outcomes and treatment response. Using the MethylMix algorithm, 14 methylation-driven genes were selected for further analysis. We confirmed...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667097/ https://www.ncbi.nlm.nih.gov/pubmed/36408176 http://dx.doi.org/10.3389/fonc.2022.1053800 |
_version_ | 1784831654988087296 |
---|---|
author | Yu, Yu-Chong Shi, Tian-Ming Gu, Sheng-Lan Li, Yu-Hong Yang, Xiao-Ming Fan, Qiong Wang, Yu-Dong |
author_facet | Yu, Yu-Chong Shi, Tian-Ming Gu, Sheng-Lan Li, Yu-Hong Yang, Xiao-Ming Fan, Qiong Wang, Yu-Dong |
author_sort | Yu, Yu-Chong |
collection | PubMed |
description | Herein, A non-invasive pathomics approach was developed to reveal the methylation status in patients with cervical squamous cell carcinoma and predict clinical outcomes and treatment response. Using the MethylMix algorithm, 14 methylation-driven genes were selected for further analysis. We confirmed that methylation-driven genes were differentially expressed in immune, stromal, and tumor cells. In addition, we constructed a methylation-driven model and explored the alterations in immunocyte infiltration between the different models. The methylation-driven subtypes identified in our investigation could effectively predict the clinical outcomes of cervical cancer. To further evaluate the level of methylation-driven patterns, we constructed a risk model with four genes. Significant correlations were observed between the score and immune response markers, including PD1 and CTLA4. Multiple immune infiltration algorithms evaluated the level of immunocyte infiltration between the high- and low-risk groups, while the components of anti-tumor immunocytes in the low-risk group were significantly increased. Subsequently, a total of 205 acquired whole-slide imaging (WSI) images were processed to capture image signatures, and the pathological algorithm was employed to construct an image prediction model based on the risk score classification. The model achieved an area under the curve (AUC) of 0.737 and 0.582 for the training and test datasets, respectively. Moreover, we conducted vitro assays for validation of hub risk gene. The proposed prediction model is a non-invasive method that combines pathomics features and genomic profiles and shows satisfactory performance in predicting patient survival and treatment response. More interdisciplinary fields combining medicine and electronics should be explored in the future. |
format | Online Article Text |
id | pubmed-9667097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96670972022-11-17 A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy Yu, Yu-Chong Shi, Tian-Ming Gu, Sheng-Lan Li, Yu-Hong Yang, Xiao-Ming Fan, Qiong Wang, Yu-Dong Front Oncol Oncology Herein, A non-invasive pathomics approach was developed to reveal the methylation status in patients with cervical squamous cell carcinoma and predict clinical outcomes and treatment response. Using the MethylMix algorithm, 14 methylation-driven genes were selected for further analysis. We confirmed that methylation-driven genes were differentially expressed in immune, stromal, and tumor cells. In addition, we constructed a methylation-driven model and explored the alterations in immunocyte infiltration between the different models. The methylation-driven subtypes identified in our investigation could effectively predict the clinical outcomes of cervical cancer. To further evaluate the level of methylation-driven patterns, we constructed a risk model with four genes. Significant correlations were observed between the score and immune response markers, including PD1 and CTLA4. Multiple immune infiltration algorithms evaluated the level of immunocyte infiltration between the high- and low-risk groups, while the components of anti-tumor immunocytes in the low-risk group were significantly increased. Subsequently, a total of 205 acquired whole-slide imaging (WSI) images were processed to capture image signatures, and the pathological algorithm was employed to construct an image prediction model based on the risk score classification. The model achieved an area under the curve (AUC) of 0.737 and 0.582 for the training and test datasets, respectively. Moreover, we conducted vitro assays for validation of hub risk gene. The proposed prediction model is a non-invasive method that combines pathomics features and genomic profiles and shows satisfactory performance in predicting patient survival and treatment response. More interdisciplinary fields combining medicine and electronics should be explored in the future. Frontiers Media S.A. 2022-11-02 /pmc/articles/PMC9667097/ /pubmed/36408176 http://dx.doi.org/10.3389/fonc.2022.1053800 Text en Copyright © 2022 Yu, Shi, Gu, Li, Yang, Fan and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yu, Yu-Chong Shi, Tian-Ming Gu, Sheng-Lan Li, Yu-Hong Yang, Xiao-Ming Fan, Qiong Wang, Yu-Dong A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title | A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title_full | A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title_fullStr | A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title_full_unstemmed | A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title_short | A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy |
title_sort | novel cervix carcinoma biomarker: pathological-epigenomics, integrated analysis of methylmix algorithm and pathology for predicting response to cancer immunotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667097/ https://www.ncbi.nlm.nih.gov/pubmed/36408176 http://dx.doi.org/10.3389/fonc.2022.1053800 |
work_keys_str_mv | AT yuyuchong anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT shitianming anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT gushenglan anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT liyuhong anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT yangxiaoming anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT fanqiong anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT wangyudong anovelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT yuyuchong novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT shitianming novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT gushenglan novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT liyuhong novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT yangxiaoming novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT fanqiong novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy AT wangyudong novelcervixcarcinomabiomarkerpathologicalepigenomicsintegratedanalysisofmethylmixalgorithmandpathologyforpredictingresponsetocancerimmunotherapy |